CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

Eli Lilly (NYSE:LLY) on Saturday announced detailed data from its ACHIEVE-1 Phase 3 trial, which reached the main goal for ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

An intervention designed to emphasize management of overweight and obesity in primary care settings was associated with ...